WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health
care company that develops wearable medical technology and point-of-care
diagnostics that helps patients and physicians better manage chronic
pain, nerve disorders, and associated sleep disturbances, today
announced an initiative to improve the detection and awareness of
diabetic peripheral neuropathy, or DPN, at a reasonable cost to
patients. The program is targeted at podiatric physicians and offers
creative commercial terms to incorporate a DPN screening program into
their clinical practice with NC-stat® DPNCheck®
technology. This objective test will allow them to more accurately
assess their patients with diabetes for DPN and enhance the podiatric
care they provide.
NC-stat DPNCheck addresses an unmet medical need for accurate and
cost-effective screening, diagnosing and monitoring of DPN. This
complication of diabetes affects over 50% of diabetics and leads to foot
ulcers and limb amputation, as well as severe pain and an overall
reduction in patient quality of life. NC-stat DPNCheck has found growing
acceptance among larger Medicare Advantage plans where the test is used
in the clinically and financially important risk adjustment process.
U.S. podiatrists number approximately 15,000. Their central role in
managing DPN and its complications positions them to advise patients on
the benefits of early DPN detection in guiding treatment. Recent studies
have not only confirmed the benefits to patients of podiatric care but
also the significant savings in health care costs due to lower risks of
hospitalization and amputation where podiatrists are involved in the
care of patients with diabetes. Screening with NC-stat DPNCheck will
help podiatrists identify patients likely to benefit from intensive
podiatric care.
"NC-stat DPNCheck is well suited to the podiatrist with a significant
diabetes practice," said Shai N. Gozani, M.D., Ph.D., President and
Chief Executive Officer of NeuroMetrix. "Patients will benefit from
awareness and treatment that more accurately takes into account their
condition. Podiatrists will find that DPN screening can be efficiently
adopted in their medical practice to improve patient risk assessment
while contributing to practice economics."
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care diagnostics that help patients and
physicians better manage chronic pain, nerve disorders, and associated
sleep disturbances. The Company has a major focus on diabetic
neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy and other forms of chronic pain such as fibromyalgia, post
herpetic neuropathy (shingles), and conditions with both chronic pain
and disturbed sleep such as restless leg syndrome. The company also
markets the DPNCheck® device, which is a rapid, accurate, and
quantitative point-of-care test for peripheral neuropathies such as
diabetic neuropathy. This product is used to detect neuropathies at an
early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
